Results 1 to 10 of about 656 (68)
Introduction:Current clinical research has reported the effectiveness and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
Xiaojing Yan
exaly +3 more sources
Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using ...
Di Wu +3 more
doaj +1 more source
In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine).
Nerea Báez-Gutiérrez +4 more
doaj +1 more source
Pseudo-differentiation syndrome
A patient with relapsed acute myeloid leukemia (AML) (M2) FAB classification developed a differentiating syndrome upon receiving Decitabine therapy given with palliative intent.
Dina Khalaf, Fathi Jehani
doaj +3 more sources
We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%.
Alicia Roldán Pérez +6 more
doaj +1 more source
Hypomethylating Agents in Oncohematology
The review describes epigenetic processes, including methylation of nuclear and mitochondrial DNA, as well as RNA. It dwells on mechanisms of demethylation and corresponding medicinal products.
Anton Dmitrievich Shirin +1 more
doaj +1 more source
Objectives: Low-dose cytarabine (LD-AraC) is still regarded as the standard of care in elderly patients with acute myeloid leukemia (AML) ‘unfit’ for intensive chemotherapy.
Maël Heiblig +12 more
doaj +1 more source
Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.
Varbanova V. +9 more
doaj +1 more source
Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia
Epigenetic alteration has been proposed to give rise to numerous classic hallmarks of cancer. Impaired DNA methylation plays a central role in the onset and progression of several types of malignancies, and DNA methylation is mediated by DNA ...
Kah Keng Wong +2 more
doaj +1 more source
The development of post-chemotherapy resistance is a significant issue in the management of AML. Here, Caiado et al. suggest that the issue might be circumvented via upfront combination with hypomethylating agents that shape the clonal dynamics and ...
Francisco Caiado +15 more
doaj +1 more source

